<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jiangsu Hengrui Medicine Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd</link>
<description>Latest news and press releases for Jiangsu Hengrui Medicine Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 09:40:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jiangsu-hengrui-medicine-co-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-profit-growth</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-reports-q1-2026-results-with-revenue-and-net-profit-growth</guid>
<pubDate>Wed, 22 Apr 2026 09:40:00 GMT</pubDate>
<description>Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.</description>
</item>
<item>
<title>Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-braveheart-bio-announce-positive-phase-2-results-with-hrsbhb-1893-in-obstructive-hypertrophic-cardiomyopathy</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-braveheart-bio-announce-positive-phase-2-results-with-hrsbhb-1893-in-obstructive-hypertrophic-cardiomyopathy</guid>
<pubDate>Mon, 30 Mar 2026 13:35:00 GMT</pubDate>
<description>Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM). In the 42 patient study, HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G), an established measure of cardiac obstruction.</description>
</item>
<item>
<title>Hengrui Pharma Announces Strong 2025 Annual Results</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-announces-strong-2025-annual-results</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-announces-strong-2025-annual-results</guid>
<pubDate>Thu, 26 Mar 2026 00:52:00 GMT</pubDate>
<description>On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.8% to RMB 7.72 billion.</description>
</item>
<item>
<title>Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China with oral GLP-1/GIP receptor dual agonist ribupatideUp to 38.6% of participants taking oral ribupatide achieved at least 15% weight lossVomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg oral ribupatide, respectivelyHengrui to rapidly advance oral ribupatide to Phase 3 trial in China; Kailera plans to initiate a global Phase 2 clinical trial in 2026 SHANGHAI, China and WALTHAM,</description>
</item>
<item>
<title>Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1gip-receptor-agonist-hrs9531</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1gip-receptor-agonist-hrs9531</guid>
<pubDate>Tue, 04 Nov 2025 17:00:00 GMT</pubDate>
<description>– Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6%I at 8 mg at week 36 with no plateau – – NDA submitted in China by Hengrui; Kailera plans to start global Phase 3 trials by year-end evaluating multiple maintenance doses including 8 mg – SHANGHAI and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharma</description>
</item>
<item>
<title>Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-reports-steady-growth-in-q3-2025-driven-by-innovation-and-global-expansion</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-reports-steady-growth-in-q3-2025-driven-by-innovation-and-global-expansion</guid>
<pubDate>Mon, 27 Oct 2025 11:34:00 GMT</pubDate>
<description>Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period last year.</description>
</item>
<item>
<title>Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-announce-phase-3-hrs9531-obesity-data-presentation-at-obesityweekr-2025</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-announce-phase-3-hrs9531-obesity-data-presentation-at-obesityweekr-2025</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>Results from Hengrui’s completed Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss, to be presented in an oral sessionSHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage por</description>
</item>
<item>
<title>Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/live-from-esmo-or-hengrui-debuts-exhibition-booth-with-landmark-data-showcasing-pharmas-emerging-innovation-power</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/live-from-esmo-or-hengrui-debuts-exhibition-booth-with-landmark-data-showcasing-pharmas-emerging-innovation-power</guid>
<pubDate>Mon, 20 Oct 2025 06:20:00 GMT</pubDate>
<description>From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma not only returned with a comprehensive portfolio of oncology research but also debuted as an exhibitor, marking a new milestone in its global academic engagement.</description>
</item>
<item>
<title>Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-glenmark-pharmaceuticals-enter-exclusive-license-agreement-for-her2-adc-trastuzumab-rezetecan-shr-a1811</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-glenmark-pharmaceuticals-enter-exclusive-license-agreement-for-her2-adc-trastuzumab-rezetecan-shr-a1811</guid>
<pubDate>Wed, 24 Sep 2025 11:45:00 GMT</pubDate>
<description>Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., which is a research-led, global pharmaceutical company, for Hengrui's independently developed HER2-targeting ADC, Trastuzumab Rezetecan (SHR-A1811).</description>
</item>
<item>
<title>Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-braveheart-bio-enter-exclusive-license-agreement-for-cardiac-myosin-inhibitor-hrs-1893</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-braveheart-bio-enter-exclusive-license-agreement-for-cardiac-myosin-inhibitor-hrs-1893</guid>
<pubDate>Fri, 05 Sep 2025 12:00:00 GMT</pubDate>
<description>Hengrui Pharma (600276.SH；01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential. Braveheart Bio is a newly launched, U.S.-based biotechnology company focused on cardiovascular disease with a consortium of lead investor</description>
</item>
<item>
<title>Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-gsk-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respiratory-immunology-and-inflammation-and-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-gsk-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respiratory-immunology-and-inflammation-and-oncology</guid>
<pubDate>Mon, 28 Jul 2025 01:53:00 GMT</pubDate>
<description>Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in-class profiles. GSK will pay $500 milli</description>
</item>
<item>
<title>IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-world-conference-on-lung-cancer-for-ide849-shr-4849-a-potential-first-in-class-dll3-top1-adc</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-world-conference-on-lung-cancer-for-ide849-shr-4849-a-potential-first-in-class-dll3-top1-adc</guid>
<pubDate>Tue, 22 Jul 2025 17:01:00 GMT</pubDate>
<description>IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spai</description>
</item>
<item>
<title>Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1gip-receptor-agonist-hrs9531</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1gip-receptor-agonist-hrs9531</guid>
<pubDate>Tue, 15 Jul 2025 11:30:00 GMT</pubDate>
<description>– Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other GLP-1-based treatments – – Hengrui to submit NDA in China; Kailera plans to evaluate both higher doses and longer duration of treatment in global clinical trials – JIANGSU, China and WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc</description>
</item>
<item>
<title>Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD</title>
<link>https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/breakthrough-in-ophthalmology-hengruis-heng-qinr-perfluorohexyloctane-eye-drops-approved-as-first-treatment-for-dry-eye-disease-associated-with-mgd</link>
<guid isPermaLink="true">https://6ix.com/company/jiangsu-hengrui-medicine-co-ltd/news/breakthrough-in-ophthalmology-hengruis-heng-qinr-perfluorohexyloctane-eye-drops-approved-as-first-treatment-for-dry-eye-disease-associated-with-mgd</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>JIANGSU, China & HEIDELBERG, Germany & CAMBRIDGE, Mass., July 08, 2025--Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma"), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyl</description>
</item>
</channel>
</rss>